Retatrutide

Retatrutide is a synthetic peptide engineered as a single-molecule "triple agonist," activating three distinct receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the GLP-1 receptor, and — unlike tirzepatide or semaglutide — the glucagon receptor. Like other modern incretin therapies, it carries a fatty-acid moiety that binds albumin to extend its half-life for once-weekly dosing. GIP/GLP-1 activity enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite, while added glucagon-receptor agonism is proposed to increase energy expenditure and hepatic fat oxidation, a mechanism hypothesized to explain the larger weight-loss effect seen with retatrutide relative to dual or single-receptor agonists.

Retatrutide is an investigational drug in active clinical development by Eli Lilly and is NOT an approved medicine anywhere as of this review. Its most-cited data come from a Phase 2 obesity trial (Jastreboff et al., NEJM 2023), in which participants without diabetes receiving the highest dose (12 mg weekly) lost a mean of approximately 24% of body weight at 48 weeks, versus roughly 2% with placebo — among the largest effects reported for an injectable incretin-based therapy to date. A separate Phase 2 trial in adults with type 2 diabetes (Rosenstock et al., Lancet 2023) reported clinically meaningful reductions in both HbA1c and body weight versus placebo and an active comparator. These are Phase 2 results only; Phase 3 trials (needed for regulatory approval) were ongoing at the time of this review, and Phase 2 effect sizes do not always hold in larger, longer Phase 3 programs.

Educational overview only — no dosing instructions in the public hub.

In published trials, the dominant adverse events have been gastrointestinal — nausea, vomiting, diarrhea, constipation, and reduced appetite — generally dose-dependent and consistent with the class of GIP/GLP-1/glucagon-based therapies, with some discontinuations due to these effects. As an agent that adds glucagon-receptor activity to the GIP/GLP-1 mechanism, its longer-term safety profile (including any effects on heart rate, which has been observed in trials, and gallbladder or pancreatic outcomes) is still being characterized in ongoing and future studies; it has not accumulated the years of post-marketing safety surveillance that exist for approved GLP-1 or GIP/GLP-1 drugs. Any product marketed outside licensed clinical trials or a future approved supply chain (e.g., unregulated 'research peptide' vials) carries additional, unquantified risk since it falls entirely outside the trial oversight that has generated the safety data described here.

Because retatrutide remains an investigational compound, the only material with any verified quality control is drug substance manufactured under GMP for Eli Lilly's clinical trial program. Any retatrutide obtained outside that program has no equivalent oversight; independent third-party certificates of analysis — HPLC purity, mass-spectrometry identity confirmation, and quantification of actual peptide content — are the minimum bar for assessing whether such material matches its label, but they cannot substitute for regulatory approval or clinical-trial-grade manufacturing controls.

Investigational new drug, not approved by the FDA, EMA, or any other regulatory authority as of this review; available only within registered clinical trials sponsored by Eli Lilly. It has no legal status as a prescribable medicine and no legitimate consumer supply chain; material sold commercially as 'retatrutide' sits entirely outside regulatory oversight regardless of how it is marketed.